GLP-1 receptors have been identified in human hair follicles
Compounding pharmacies and outsourcing facilities were largely supposed to stop making their own versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro, last month after the FDA determined the branded versions were no longer in shortage
BMI Standards (Commonly Used Criteria): For weight management purposes, GLP-1 medications are typically considered for individuals with: BMI of 30 or higher (obesity), OR BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.) These are general clinical guidelines used in FDA-approved product labeling and may inform provider decisions
If an individual considers it a problem, then there is a solution
The sensible move is to treat documentation, purity, and reliable handling as the baseline you pay for, then compare prices only among suppliers that clear that bar
